// App-Quantinova.ai

7549 : NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma.

Researchers

Presenter

  • David Granger

Principal Investigators

  • Satyen Gohil

  • Alessandro Barbarulo

  • Annalisa Baccaro

  • Vincent Muczynski

  • Kerry Chester

  • Fiona Germaschewski

  • Toby Batten

  • Kathryn Brown

  • Sarah Cook

  • Kieran O'Donovan

  • Parag Jasani

  • Amit C. Nathwani

  • Peter Phillips

Medical Centers

  • Dolon Ltd, London, United Kingdom

  • Kings College London, London, United Kingdom

  • Navigant, London, United Kingdom

  • NovalGen Ltd, Middlesex, United Kingdom

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Delos Consultancy Limited, Cambridge, United Kingdom

  • Veramed Ltd, Twickenham, United Kingdom,

  • Phastar, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved